JP2025511854A5 - - Google Patents

Info

Publication number
JP2025511854A5
JP2025511854A5 JP2024559398A JP2024559398A JP2025511854A5 JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5 JP 2024559398 A JP2024559398 A JP 2024559398A JP 2024559398 A JP2024559398 A JP 2024559398A JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nucleotide sequence
human subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065487 external-priority patent/WO2023196941A1/en
Publication of JP2025511854A publication Critical patent/JP2025511854A/ja
Publication of JP2025511854A5 publication Critical patent/JP2025511854A5/ja
Pending legal-status Critical Current

Links

JP2024559398A 2022-04-08 2023-04-07 非アルコール性脂肪肝疾患の治療 Pending JP2025511854A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329081P 2022-04-08 2022-04-08
US63/329,081 2022-04-08
US202263401858P 2022-08-29 2022-08-29
US63/401,858 2022-08-29
PCT/US2023/065487 WO2023196941A1 (en) 2022-04-08 2023-04-07 Treatment of a non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2025511854A JP2025511854A (ja) 2025-04-16
JP2025511854A5 true JP2025511854A5 (cg-RX-API-DMAC7.html) 2026-04-09

Family

ID=86286479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559398A Pending JP2025511854A (ja) 2022-04-08 2023-04-07 非アルコール性脂肪肝疾患の治療

Country Status (6)

Country Link
US (1) US20250283089A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504337A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511854A (cg-RX-API-DMAC7.html)
CN (1) CN119789859A (cg-RX-API-DMAC7.html)
CA (1) CA3247602A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023196941A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025074157A1 (en) * 2023-10-06 2025-04-10 Glaxosmithkline Intellectual Property (No.3) Limited Treatment of a non-alcoholic fatty liver disease
TW202540424A (zh) * 2024-02-03 2025-10-16 大陸商北京福元醫藥股份有限公司 用於抑制HSD17B13表達的siRNA、其綴合物和藥物組合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170057B1 (ar) 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
MX2020001912A (es) * 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
US12534728B2 (en) 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
KR20220158011A (ko) * 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법

Similar Documents

Publication Publication Date Title
JP7674420B2 (ja) Ldhaの発現を阻害するための方法及び組成物
JP2022501040A5 (cg-RX-API-DMAC7.html)
ES2676146T3 (es) Composiciones de ARNi de Serpina1 y métodos de uso de las mismas
JP6370860B2 (ja) 被験体におけるsmn2スプライシングのモジュレーションのための組成物および方法
JP2021518125A5 (cg-RX-API-DMAC7.html)
JP2019504112A5 (cg-RX-API-DMAC7.html)
JP2019500345A (ja) 肝臓病の処置のための組成物および方法
JP2024515423A5 (cg-RX-API-DMAC7.html)
JP2024508896A5 (cg-RX-API-DMAC7.html)
WO2023278802A1 (en) Formulations for oral delivery of nucleic acids
JP2024516356A5 (cg-RX-API-DMAC7.html)
US20240043847A1 (en) New therapy
JP2019500334A (ja) がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター4(mct4)アンチセンスオリゴヌクレオチド(aso)阻害剤
JP2023529903A5 (cg-RX-API-DMAC7.html)
JP2024522996A5 (cg-RX-API-DMAC7.html)
JP2022543136A5 (cg-RX-API-DMAC7.html)
RU2766356C2 (ru) Кобитолимод для применения при лечении воспалительного заболевания кишечника
JP2025511854A (ja) 非アルコール性脂肪肝疾患の治療
Wang et al. Aptamer-functionalized-nanoflower loading allicin ameliorates obesity through regulating adipose tissue energy expenditure
TW202434264A (zh) 降低一級預防受試者中重大不良心血管事件風險之方法
CN111630169A (zh) 用于治疗溃疡性结肠炎患者的组合物及其作为药物的用途
JP2024530030A (ja) 非天然核酸リガンドを有効成分として含む三重陰性乳癌の治療のための薬学的組成物
CN113226461A (zh) 新疗法
Gizem et al. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
CN121003688A (zh) 一种dsRNA与干扰素的联合治疗